Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
Study Identifier:
ALXN1210-MG-319
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Ravulizumab
Date
Jun 2023 - Jul 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Ravulizumab
Date
Jun 2023 - Jul 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information
Protocol Summary
The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.
Trial Locations
Location
Status
Location
Research Site
Los Angeles, California, United States, 90078
Status
Recruiting
Location
Research Site
San Francisco, California, United States, 94143
Status
Recruiting
Location
Research Site
Chicago, Illinois, United States, 60611
Status
Recruiting
Location
Research Site
Boston, Massachusetts, United States, 02115
Status
Recruiting
Location
Research Site
Chapel Hill, North Carolina, United States, 27514
Status
Recruiting
Location
Research Site
Akron, Ohio, United States, 44308
Status
Recruiting